LIVZON PHARMA (01513.HK): Tiange Dingxuan wins trial approval
- The formula contains Gastrodia elata and Pueraria lobata and is intended to dispel wind, resolve phlegm and relieve vertigo, with each bag containing 7 g.
- Cumulative direct R&D spending on the product reached about RMB 7.3358 million.
NewTimeSpace News: On 27 October 2026, Livzon Pharmaceutical Group Inc. (stock code: 01513.HK) said its subsidiary Sichuan Guangda Pharmaceutical Manufacturing Co., Ltd. received a Drug Clinical Trial Approval Notice (No. 2026LP03296) from the National Medical Products Administration to test Tiange Dingxuan Granules in vestibular migraine. It is a Class 1.1 traditional Chinese medicine, with the application accepted on 17 August 2026.
The formula contains Gastrodia elata and Pueraria lobata and is intended to dispel wind, resolve phlegm and relieve vertigo. It is China's first Class 1.1 traditional Chinese medicine to enter registered clinical trials targeting vestibular migraine. The product was developed with Dongfang Hospital of Beijing University of Chinese Medicine, with the Company holding all global rights; cumulative direct R&D spending reached about RMB 7.3358 million. Trials and regulatory approval are still required before launch.
- LIVZON PHARMA (01513.HK): Wandai Tang Granules win approval
- LIVZON PHARMA (01513.HK): Leuprorelin 3-Month Formulation Approved
- LIVZON PHARMA (01513.HK): Proposes Appointment of Zhu Linlin as Non-Executive Director of the Twelfth Board
- LIVZON PHARMA (01513.HK): Zhu Baoguo resigns as Chairman on retirement; President Liu Daping appointed
- LIVZON PHARMA (01513.HK): Lecankitug injection approved for marketing; first domestic IL-17A/F dual-target biologic in China
